Korean Drug Companies Eye Overseas Markets - (The Korea Bizwire via NewsPoints Desk)

  • According to industry sources, South Korea's major pharmaceuticals manufacturers have set their sights on overseas markets this year as a string of their biosimilars are waiting to be approved or launched, reported The Korea Bizwire.

  • Celltrion said sales of its drug Remsima SC, a biosimilar of Johnson & Johnson's Remicade for the treatment of autoimmune diseases, are set to kick off in Europe in March.

  • Meanwhile, Samsung Bioepis is awaiting approval of its treatment SB8 from health authorities in both Europe and the US.

  • The company also said it will launch its biosimilar cancer drug Ontruzant in the US during the first quarter of this year after receiving approval more than a year ago.

  • The belated launch comes as Samsung Bioepis finally settled a patent dispute with Roche's Genentech unit to reach a license deal agreement.

  • Ontruzant, a biosimilar referencing Roche's breast cancer drug Herceptin, is already sold in Europe.

To read more NewsPoints articles, click here.

Reference Articles